JAGUAR HEALTH, INC. (JAGX) Provides Business Update
JAGUAR HEALTH, INC. (JAGX) issued a business update covering recent developments.
🔍 Detailed Event Analysis:
AI Summary: The Company’s Common Stock will begin trading on a split-adjusted basis when the market opens on the Effective Date and will remain listed on The Nasdaq Capital Market under the symbol “JAGX. (Nasdaq: JAGX) (“Jaguar” or the “Company”) today announced that on April 24, 2026, the Company received formal notice that the Nasdaq Hearings Panel (the “Panel”) has granted Jaguar an extension through May 15, 2026, to demonstrate compliance with the $1. To evidence compliance, the Company must report a closing bid price of at least $1.
Key Elements Identified:
Drugs/Compounds: determination, number
Diseases/Conditions: up to 20 business days
Organizations: Demonstrate Compliance, JAGX, the Company’s C
📋 JAGUAR HEALTH, INC. (JAGX) - Other Event
Filing Date: 2026-04-27
Accepted: 2026-04-27 09:10:06
Event Type: Other Event
Event Details:
🔍 Detailed Event Analysis:
AI Summary: The Company’s Common Stock will begin trading on a split-adjusted basis when the market opens on the Effective Date and will remain listed on The Nasdaq Capital Market under the symbol “JAGX. (Nasdaq: JAGX) (“Jaguar” or the “Company”) today announced that on April 24, 2026, the Company received formal notice that the Nasdaq Hearings Panel (the “Panel”) has granted Jaguar an extension through May 15, 2026, to demonstrate compliance with the $1. To evidence compliance, the Company must report a closing bid price of at least $1.
Key Elements Identified:
💼 Business Developments:
Structured Data: